# CJC-1295 Research Review: The Human and Preclinical Record > CJC-1295 research, reviewed by evidence state: human PK (Teichman 2006, Ionescu/Frohman 2006), the rat albumin-conjugate study (Jette 2005), the GHRH-analog class, and CJC-1295 + ipamorelin. Cited. The human pharmacokinetics, the rat proof-of-concept, the class it belongs to, and the ipamorelin pairing — each tagged confirmed, preclinical, or gap, and each logged to its source. ## What the human studies measured The human record for CJC-1295 is small, early, and consistent. In healthy adults, single subcutaneous doses of 30 or 60 micrograms/kg produced dose-dependent 2- to 10-fold increases in mean plasma growth hormone lasting six days or more, and 1.5- to 3-fold increases in IGF-1 lasting nine to eleven days [1]. After multiple doses, IGF-1 remained above baseline for up to 28 days, and the analysis estimated a CJC-1295 half-life of 5.8 to 8.1 days [1]. A second study sharpened the picture. In healthy men aged 20 to 40, a single subcutaneous dose of 60 or 90 micrograms/kg raised basal GH approximately 7.5-fold, mean GH by about 46%, and IGF-1 by about 45% one week later — while the frequency and amplitude of pulsatile GH secretion were unchanged [3]. That last point is the structurally interesting one: under continuous stimulation by a long-acting GHRH analog, the pituitary kept releasing GH in pulses rather than as a flat plateau [3]. A later proteomic study in eleven healthy young men found reproducible serum protein shifts that correlated with the IGF-1 response, offering candidate biomarkers of GH/IGF-1-axis activation [5]. ## How strong is the evidence? Strong on kinetics, thin on outcomes. The pharmacokinetic and pharmacodynamic behavior of CJC-1295 — how much GH and IGF-1 it raises, for how long, by which mechanism — is documented in peer-reviewed human studies [1][3]. That is the confirmed core of any honest CJC-1295 review. ### How strong is the evidence? Limited. The published human record consists of early-phase pharmacokinetic studies in small groups of healthy volunteers (Teichman 2006; Ionescu and Frohman 2006). A ConjuChem Phase 2 program in HIV-associated visceral obesity was discontinued, and no large efficacy or long-term safety trials in healthy adults exist [1]. Claims about body composition, muscle gain, or "anti-aging" outcomes are not supported by controlled human outcome data — they extrapolate from the GH/IGF-1 biomarker response. That is the whole appraisal: the biomarker response is real and reproducible; the downstream clinical outcomes in healthy adults are unstudied. A research review that treats those two states as one is the single most common error in the popular literature on this compound. ## The rat study that proved the design The DAC concept was validated before any human dosing. A series of hGRF(1-29) analogs carrying a C-terminal maleimidopropionyl-lysine handle were screened; the lead candidate, CJC-1295, combined four DPP-IV-protective substitutions with covalent bioconjugation to circulating serum albumin [2]. In Sprague-Dawley rats it produced a 4-fold increase in GH area-under-the-curve over two hours versus the unconjugated peptide, remained detectable in plasma beyond 72 hours, and showed enhanced in-vitro stability against dipeptidylpeptidase-IV [2]. The mouse work then closed the loop on dosing frequency. In GHRH-knockout mice, 2 micrograms of CJC-1295 every 24 hours fully normalized body weight and length, while dosing every 48 to 72 hours was progressively less effective; treatment also raised pituitary GH mRNA [4]. Together these studies establish the mechanistic claim: a long-acting, albumin-bound GHRH analog can drive the GH axis on an infrequent schedule [2][4]. ## What is a GHRH analog? Reading CJC-1295 well means reading its class. ### What is a GHRH analog? A GHRH analog is a synthetic molecule that mimics growth-hormone-releasing hormone — the hypothalamic signal that tells the pituitary to make and release growth hormone. CJC-1295, sermorelin, and tesamorelin are all GHRH analogs; they bind the GHRH receptor (a class B G-protein-coupled receptor) on pituitary somatotrophs and activate the Gs/cAMP/PKA pathway that drives GH gene transcription [3]. The released GH then acts on hepatic GH receptors to raise IGF-1. A 2024/2025 Nature Reviews Endocrinology review synthesizes the pharmacology of GHRH and its synthetic analogues — the class that includes CJC-1295 — describing receptor signaling, the rationale for long-acting analog design, and the therapeutic and investigational landscape [13]. The closest FDA-approved comparator in the class is tesamorelin, studied in HIV-associated fat accumulation; CJC-1295 itself has no approved indication [1]. ## CJC-1295 and ipamorelin: the two-receptor rationale The most-discussed CJC-1295 pairing is with ipamorelin, and the rationale is mechanistic, not a clinical outcome trial. GHRH analogs and growth-hormone-releasing peptides (GHRPs) act through distinct receptors — the GHRH receptor and the ghrelin/GHS receptor — so co-administration can produce GH release greater than either alone [11]. Ipamorelin is the partner most often cited because it is a selective GH secretagogue with quantified pharmacokinetic-pharmacodynamic behavior [11]. ### Does CJC-1295 and ipamorelin work? GHRH analogs and GHRPs act through distinct receptors and synergize, so co-administration produces greater acute GH release than either alone. Published data are on the acute GH/IGF-1 response, not on long-term body-composition outcomes in healthy adults. ### What is CJC-1295 ipamorelin? A research pairing of a GHRH analog (CJC-1295) with a selective GH secretagogue (ipamorelin). Because the two act on different receptors, co-administration produces greater GH release than either alone — the rationale behind the combination. ### How much CJC-1295 / ipamorelin should I take? There is no validated human dose for the combination. Community "protocols" pair fixed microgram amounts of each, but these are not derived from controlled human trials; the published basis is only the acute two-receptor GH synergy seen when a GHRH analog and a GHRP are co-administered. --- The CJC-1295 record read as a state machine — each figure logged to its study and tagged confirmed, the absent long-term human safety data left in plain view as the loudest state on the panel; no clinic behind the interface and nothing here dispensed or sold.